Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
PHILADELPHIA, Dec. 5, 2012 /PRNewswire via COMTEX/ --
The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced a preview of its newest intelligence solution, Thomson Reuters Cortellis(TM) for Clinical Trials Intelligence. Scheduled for release in early 2013, this capability will provide drug development and clinical professionals with the critical information necessary to evaluate market opportunities, identify potential barriers, and establish informed decisions about clinical trial design and operations.
Cortellis for Clinical Trials Intelligence is the latest information solution offered through Thomson Reuters Cortellis, the industry's premier Life Sciences information delivery platform. It has the broadest remit of any clinical trials database including a 45-year history of clinical outcomes, as well as the latest market competitive activity from established and emerging markets such as China, India and Brazil. It is the only solution that enables a customer to integrate their proprietary research data with comprehensive clinical trials protocols and outcomes, drug pipeline, biomarker, regulatory, financial and patent information from Thomson Reuters. With its integrated analytics tools and visualizations, users will have greater opportunities to maximize the value of clinical trial content to inform internal strategy and decision-making.
"Cortellis for Clinical Trials Intelligence provides comprehensive clinical trial protocols and outcomes with global reach and integrates with other key intelligence areas - such as patents and literature - to allow for the broadest possible perspectives and actionable insights," said Jon Brett-Harris, executive vice president at Thomson Reuters. "However, it is not just an information web portal. We are also providing multiple delivery options, such as dynamic real-time visualizations, iPad support and application programming interfaces to assist our customers in integrating it with their existing knowledge platforms and workflow solutions."
Cortellis for Clinical Trials Intelligence optimizes critical clinical trial functions by equipping R&D strategists with knowledge that helps them discover market opportunities and potential barriers. This solution enables efficient searching for competing trials as well as identifying countries rich in target populations. By empowering clinical development teams to better understand trial design trends, Cortellis for Clinical Trials Intelligence allows them to design better and faster trials, while enabling marketing teams to pinpoint likely competitors.
The experts of Thomson Reuters' professional services also utilize Cortellis for Clinical Trial Intelligence and the company's other intelligence solutions - including translational medicine offerings and clinical development and portfolio strategy benchmarking - to support specific customer projects. Thomson Reuters has more than 15 years of experience supporting clinical development in the optimization of global clinical performance metrics, analysis and trending through its business, CMR International.
For more information on Cortellis, visit cortellis.thomsonreuters.com.
Thomson Reuters Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.
SOURCE Thomson Reuters
[ Back To IBM News 's Homepage ]